본문 바로가기
KERD
논문KCI 등재

Treatment Outcomes of Olfactory Neuroblastoma: A Multicenter Study by the Korean Sinonasal Tumor and Skull Base Surgery Study Group

조성우|김지희|박수경|조현진|이동훈|김동영|박송이|김용완|문수진|원태빈|홍상덕|허성재
대한이비인후과학회 (Korean Society of Otorhinolaryngology-Head and Neck Surgery)|2024.05|Clinical and Experimental Otorhinolaryngology|제17권 제2호|pp. 137-146|DOI https://doi.org/10.21053/ceo.2023.00089

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

PrognosisTreatment OutcomeKeywords. EsthesioneuroblastomaNeoadjuvant Therapy

초록

Objectives. Due to the rarity of olfactory neuroblastoma (ONB), there is ongoing debate about optimal treatment strategies,especially for early-stage or locally advanced cases. Therefore, our study aimed to explore experiences from multiplecenters to identify factors that influence the oncological outcomes of ONB. Methods. We retrospectively analyzed 195 ONB patients treated at nine tertiary hospitals in South Korea between Decem-ber 1992 and December 2019. Kaplan-Meier survival analysis was used to evaluate oncological outcomes, and a Coxproportional hazards regression model was employed to analyze prognostic factors for survival outcomes. Further-more, we conducted 1:1 nearest-neighbor matching to investigate differences in clinical outcomes according to theuse of neoadjuvant chemotherapy. Results. In our cohort, the 5-year overall survival (OS) rate was 78.6%, and the 5-year disease-free survival (DFS) rate was62.4%. The Cox proportional hazards model revealed that the modified Kadish (mKadish) stage and Dulguerov Tstatus were significantly associated with DFS, while the mKadish stage and Hyams grade were identified as prognos-tic factors for OS. The subgroup analyses indicated a trend toward improved 5-year DFS with dural resection in mKadishA and B cases, even though the result was statistically insignificant. Induction chemotherapy did not provide a surviv-al benefit in this study after matching for the mKadish stage and nodal status. Conclusion. Clinical staging and pathologic grading are important prognostic factors in ONB. Dural resection in mKadish Aand B did not show a significant survival benefit. Similarly, induction chemotherapy also did not show a survival ben-efit, even after stage matching.

Abstract

Objectives. Due to the rarity of olfactory neuroblastoma (ONB), there is ongoing debate about optimal treatment strategies,especially for early-stage or locally advanced cases. Therefore, our study aimed to explore experiences from multiplecenters to identify factors that influence the oncological outcomes of ONB. Methods. We retrospectively analyzed 195 ONB patients treated at nine tertiary hospitals in South Korea between Decem-ber 1992 and December 2019. Kaplan-Meier survival analysis was used to evaluate oncological outcomes, and a Coxproportional hazards regression model was employed to analyze prognostic factors for survival outcomes. Further-more, we conducted 1:1 nearest-neighbor matching to investigate differences in clinical outcomes according to theuse of neoadjuvant chemotherapy. Results. In our cohort, the 5-year overall survival (OS) rate was 78.6%, and the 5-year disease-free survival (DFS) rate was62.4%. The Cox proportional hazards model revealed that the modified Kadish (mKadish) stage and Dulguerov Tstatus were significantly associated with DFS, while the mKadish stage and Hyams grade were identified as prognos-tic factors for OS. The subgroup analyses indicated a trend toward improved 5-year DFS with dural resection in mKadishA and B cases, even though the result was statistically insignificant. Induction chemotherapy did not provide a surviv-al benefit in this study after matching for the mKadish stage and nodal status. Conclusion. Clinical staging and pathologic grading are important prognostic factors in ONB. Dural resection in mKadish Aand B did not show a significant survival benefit. Similarly, induction chemotherapy also did not show a survival ben-efit, even after stage matching.

참고문헌 (43)

  1. Arnold MA, "Comparing Kadish and modified Dulguerov staging systems for olfactory neuroblastoma : an individual participant data meta-analysis", Otolaryngol Head Neck Surg, 163(3), pp.418~427 (2020)
  2. Marinelli JP, "Dural invasion predicts the laterality and development of neck metastases in esthesioneuroblastoma", J Neurol Surg B Skull Base, 79(5), pp.495~500 (2018)
  3. Ferlito A, "Contemporary clinical commentary : esthesioneuroblastoma : an update on management of the neck", Laryngoscope, 113(11), pp.1935~1938 (2003)
  4. Kumar M, "Esthesioneuroblastoma in children", J Pediatr Hematol Oncol, 24(6), pp.482~487 (2002)
  5. Ow TJ, "Esthesioneuroblastoma", Neurosurg Clin N Am, 24(1), pp.51~65 (2013)
  6. Schmidt C, "Olfactory neuroblastoma : 14-year experience at an Australian tertiary centre and the role for longer-term surveillance", J Laryngol Otol, 131(S2), pp.S29~S34 (2017)
  7. Hirose T, "Olfactory neuroblastoma. An immunohistochemical, ultrastructural, and flow cytometric study", Cancer, 76(1), pp.4~19 (1995)
  8. Kadish S, "Olfactory neuroblastoma : a clinical analysis of 17 cases", Cancer, 37(3), pp.1571~1576 (1976)
  9. Morita A, "Esthesioneuroblastoma : prognosis and management", Neurosurgery, 32(5), pp.706~714 (1993)
  10. Dulguerov P, "Esthesioneuroblastoma : the UCLA experience 1970-1990", Laryngoscope, 102(8), pp.843~849 (1992)
  11. Hyams VJ, "Tumors of the upper respiratory tract and ear" (1988), Armed Forces Institute of Pathology
  12. Su SY, "Outcomes for olfactory neuroblastoma treated with induction chemotherapy", Head Neck, 39(8), pp.1671~1679 (2017)
  13. Miller KC, "Induction therapy prior to surgical resection for patients presenting with locally advanced esthesioneuroblastoma", J Neurol Surg B Skull Base, 82(Suppl 3), pp.e131~e137 (2021)
  14. Broich G, "Esthesioneuroblastoma: a general review of the cases published since the discovery of the tumour in 1924", Anticancer Res, 17(4A), pp.2683~2706 (1997)
  15. Dulguerov P, "Esthesioneuroblastoma : a meta-analysis and review", Lancet Oncol, 2(11), pp.683~690 (2001)
  16. Gruber G, "Esthesioneuroblastoma : irradiation alone and surgery alone are not enough", Int J Radiat Oncol Biol Phys, 54(2), pp.486~491 (2002)
  17. Diaz EM, "Olfactory neuroblastoma : the 22-year experience at one comprehensive cancer center", Head Neck, 27(2), pp.138~149 (2005)
  18. Jethanamest D, "Esthesioneuroblastoma : a population-based analysis of survival and prognostic factors", Arch Otolaryngol Head Neck Surg, 133(3), pp.276~280 (2007)
  19. Van Gompel JJ, "Long-term outcome of esthesioneuroblastoma : hyams grade predicts patient survival", J Neurol Surg B Skull Base, 73(5), pp.331~336 (2012)
  20. Capelle L, "Esthesioneuroblastoma : a case report of diffuse subdural recurrence and review of recently published studies", J Med Imaging Radiat Oncol, 52(1), pp.85~90 (2008)
  21. Bachar G, "Esthesioneuroblastoma : the Princess Margaret Hospital experience", Head Neck, 30(12), pp.1607~1614 (2008)
  22. Prasad KC, "Endoscopic-assisted excision of esthesioneuroblastoma", J Craniofac Surg, 18(5), pp.1034~1038 (2007)
  23. Fitzek MM, "Neuroendocrine tumors of the sinonasal tract : results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy", Cancer, 94(10), pp.2623~2634 (2002)
  24. Eich HT, "Multimodality therapy including radiotherapy and chemotherapy improves event-free survival in stage C esthesioneuroblastoma", Strahlenther Onkol, 179(4), pp.233~240 (2003)
  25. Bradley PJ, "Diagnosis and management of esthesioneuroblastoma", Curr Opin Otolaryngol Head Neck Surg, 11(2), pp.112~118 (2003)
  26. Kim HJ, "Surgical treatment versus concurrent chemoradiotherapy as an initial treatment modality in advanced olfactory neuroblastoma", Auris Nasus Larynx, 34(4), pp.493~498 (2007)
  27. Rimmer J, "Olfactory neuroblastoma : a 35-year experience and suggested follow-up protocol", Laryngoscope, 124(7), pp.1542~1549 (2014)
  28. McMillan RA, "Long-term oncologic outcomes in esthesioneuroblastoma : an institutional experience of 143 patients", Int Forum Allergy Rhinol, 12(12), pp.1457~1467 (2022)
  29. Sun M, "Long-term analysis of multimodality treatment outcomes and prognosis of esthesioneuroblastomas : a single center results of 138 patients", Radiat Oncol, 15(1), pp.219~ (2020)
  30. Choby G, "Multicenter survival analysis and application of an olfactory neuroblastoma staging modification incorporating Hyams grade", JAMA Otolaryngol Head Neck Surg, 149(9), pp.837~844 (2023)
  31. Ketcham AS, "A combined intracranial facial approach to the paranasal sinuses", Am J Surg, 106, pp.698~703 (1963)
  32. Mays AC, "Early stage olfactory neuroblastoma and the impact of resecting dura and olfactory bulb", Laryngoscope, 128(6), pp.1274~1280 (2018)
  33. Hanna E, "Endoscopic resection of sinonasal cancers with and without craniotomy : oncologic results", Arch Otolaryngol Head Neck Surg, 135(12), pp.1219~1224 (2009)
  34. Geltzeiler M, "Radiographic predictors of occult intracranial involvement in olfactory neuroblastoma patients", Int Forum Allergy Rhinol, 13(10), pp.1876~1888 (2023)
  35. Thompson LD, "Olfactory neuroblastoma", Head Neck Pathol, 3(3), pp.252~259 (2009)
  36. Ozsahin M, "Outcome and prognostic factors in olfactory neuroblastoma : a rare cancer network study", Int J Radiat Oncol Biol Phys, 78(4), pp.992~997 (2010)
  37. Bhattacharyya N, "Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation : results in 9 cases", Arch Otolaryngol Head Neck Surg, 123(1), pp.34~40 (1997)
  38. Saade RE, "Prognosis and biology in esthesioneuroblastoma : the emerging role of Hyams grading system", Curr Oncol Rep, 17(1), pp.423~ (2015)
  39. Loy AH, "Esthesioneuroblastoma : continued follow-up of a single institution’s experience", Arch Otolaryngol Head Neck Surg, 132(2), pp.134~138 (2006)
  40. Platek ME, "Improved survival following surgery and radiation therapy for olfactory neuroblastoma : analysis of the SEER database", Radiat Oncol, 6, pp.41~ (2011)
  41. Ow TJ, "Optimization of long-term outcomes for patients with esthesioneuroblastoma", Head Neck, 36(4), pp.524~530 (2014)
  42. Patil VM, "Neoadjuvant chemotherapy in locally advanced and borderline resectable nonsquamous sinonasal tumors(esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation)", Int J Surg Oncol, 2016, pp.6923730~ (2016)
  43. Kim DW, "Neoadjuvant etoposide, ifosfamide, and cisplatin for the treatment of olfactory neuroblastoma", Cancer, 101(10), pp.2257~2260 (2004)

관련 논문AI추천

Endoscopic Versus Traditional Craniofacial Resection for Patients with Sinonasal Tumors Involving the Anterior Skull Base김대우, 김동영, 김봉직, 김시환, 이재서, 이철희, 한두희대한이비인후과학회 · Clinical and Experimental Otorhinolaryngology2008 · 제1권 제3호비·부비동 악성종양에서 순수 내시경 절제술과 내시경절제술과외부접근법을 병용한 환자의 치료성적 비교고진영, 김배현, 김용완, 노환중, 조규섭대한이비인후과학회 부산,울산,경남 지부회 · 임상이비인후과2011 · 제22권 제1호재발성 후각신경아세포종 환자에서의 감마나이프수술 1예노환중, 박다희, 성순기, 이근익대한이비인후과학회 부산,울산,경남 지부회 · 임상이비인후과2023 · 제34권 제2호후신경아세포종의 치료 결과 분석：11예김규보, 김창훈, 김현직, 신유섭, 윤주헌, 이헌석대한이비인후과학회 · 대한이비인후과학회지 두경부외과학2006 · 제49권 제7호Neuroendocrine Tumor Grade 2 of the Nasal Cavity: Case Report and Review of Literature박승진, 신민준, 여남경대한이비인후과학회 부산,울산,경남 지부회 · 임상이비인후과2020 · 제31권 제2호The Search for an Ideal Definitive Treatment of Sinonasal Squamous Cell Carcinoma With Orbit Invasion성전, 김동영, 김정훈, 김현직, 원태빈, 이재서, 조성우, 한승철대한이비인후과학회 · Clinical and Experimental Otorhinolaryngology2024 · 제17권 제3호

이 간행물의 다른 논문 (8건)

Electrically Evoked Auditory Brainstem Response Using Extracochlear Stimulation at Different Cochlear Sites: A Comparison With Intracochlear Stimulation선우웅상, 구운회, 오승하pp. 99-108Deterioration of Hearing Due to Hearing Aids허윤진, 조양선pp. 109-115Positive Airway Pressure Therapy Compliance in Patients With Comorbid Insomnia and Sleep Apnea정석훈, 이영하, 이세원, 배미례, 정유삼pp. 116-121MicroRNA-145-5p Regulates the Epithelial-Mesenchymal Transition in Nasal Polyps by Targeting Smad3Xiaolong Liang, Mengyu Zhang, Manyi Li, Xiaomin Lu, Xiaole Peng, Wentao Wang, Yuqing Yang, Fan Xu, Dechun Gengpp. 122-136Effect of Air Pollutants on Allergic Inflammation in Structural Cells of the Nasal Mucosa양현우, 박주후, 박일호, 문지원, 송대진pp. 147-159
원문 보기